Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy

BMC Cancer

Table 1 Correlation of total PIAS3 with clinicopathological characteristics in breast cancer

Characteristics	n (%)	PIAS3		P value^a
Characteristics	n (%)	C ≦ N	C > N	P value^a
Stage				0.064
I	30 (30.0)	14	16
II	44 (44.0)	28	16
III	26 (26.0)	20	6
Estrogen receptor status				0.852
Negative	38 (38.0)	24	14
Positive	62 (62.0)	38	24
Progesterone receptor status				0.843
Negative	54 (54.0)	33	21
Positive	46 (46.0)	29	17
Her2/Neu status^b				0.193
Negative	34 (35.1)	24	10
Positive	63 (64.9)	36	27
Lymph node metastasis status				0.071
Absent	49 (49.0)	26	23
Present	51 (51.0)	36	15

N, adjacent non-cancerous breast tissue; C, cancerous breast tissue; ^a, X ² test; ^b, not determined in a small subset of the cases

ISSN: 1471-2407